Polypharmacy in the HIV-infected older adult population
Lauren J Gleason1, Amneris E Luque2, Krupa Shah1 1Division of Geriatrics and Aging, Highland Hospital, Rochester, NY, USA; 2Division of Infectious Disease, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA Abstract: The prevalence of human immunode...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fa7174f75b7244aaafb195ad5740a4ef |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Lauren J Gleason1, Amneris E Luque2, Krupa Shah1 1Division of Geriatrics and Aging, Highland Hospital, Rochester, NY, USA; 2Division of Infectious Disease, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA Abstract: The prevalence of human immunodeficiency virus (HIV) infection among people older than 50 years is increasing. Older HIV-infected patients are particularly at risk for polypharmacy because they often have multiple comorbidities that require pharmacotherapy. Overall, there is not much known with respect to both the impact of aging on medication use in HIV-infected individuals, and the potential for interactions with highly active antiretroviral therapy (HAART) and coadministered medications and its clinical consequences. In this review, we aim to provide an overview of polypharmacy with a focus on its impact on the HIV-infected older adult population and to also provide some clinical considerations in this high-risk population. Keywords: HIV, older adults, polypharmacy |
|---|